Allergan drops Valeant-Ackman insider trading lawsuit

Allergan--now owned by Actavis ($ACT)--and its former hostile suitors, Valeant ($VRX) and Bill Ackman's Pershing Square, are putting the past behind them. Actavis has agreed to drop a lawsuit accusing the tandem of insider trading, and the takeover team is withdrawing its claims that Allergan made false statements about the Canadian pharma's business model, The Wall Street Journal reports. More (sub. req.)

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.